High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER
Executive Summary
There are as many rare disease patients as there are diabetics, Cigna’s Steve Miller notes, arguing that exorbitant prices for each treatment could drive counterproductive categorical exclusions by payers.
You may also be interested in...
US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
The Cost Of ‘Stacking’ Orphan Indications And A Case For Reform
Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.
PBM Reforms: House Hearing Suggests Bipartisan Consensus On Legislative Policies Has Limits
There was lots of criticism of pharmacy benefit managers (and a fair amount of pharmaceutical manufacturers) at the oversight hearing. However, Democrats may be more cautious about preserving the benefits PBMs provide versus the downsides in developing reforms.